Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial
Year: 2023
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Authors: Kara L Kliewer, Cristin Murray-Petzold, Margaret H Collins, Juan P Abonia, Scott M Bolton, Lauren A DiTommaso, Lisa J Martin, Xue Zhang, Vincent A Mukkada, Philip E Putnam, Erinn S Kellner, Ashley L Devonshire, Justin T Schwartz, Vidhya A Kunnathur, Chen E Rosenberg, John L Lyles, Tetsuo Shoda, Amy D Klion, Marc E Rothenberg
Language: English
Topic: Eosinophilic Esophagitis
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: AstraZeneca UK, Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, American Gastroenterological Association, American Partnership for Eosinophilic Disorders, Regeneron Pharmaceuticals, Campaign Urging Research for Eosinophilic Disease, Celldex Therapeutics, Cures Within Reach, MedImmune, National Institutes of Health, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, H2020 European Research Council, NHLBI Division of Intramural Research
OpenAlex ID: W4380884580